Menu

Experience

Josh Kaufman

    • IN8bio – $40 Million IPO 


    • Sprinklr – $293 Million IPO 


    • Centessa Pharmaceuticals – $380 Million IPO 


    • LAVA Therapeutics – $107 Million IPO 


    • Gamida Cell Closes $75 Million Financing With Highbridge Capital Management  


    • Advises Anchiano Therapeutics Ltd on its reverse-merger with Chemomab 


    • Orphazyme – $84 Million IPO 


    • COMPASS Pathways – $147 Million IPO 


    • PolyPid – $69 Million IPO 


    • Calliditas Therapeutics - $90 Million IPO 


    • Bavarian Nordic - DKK$2.7 Billion Rights Issue 


    • Shake Shack - $215 Million Combined Secondary Offerings 


    • Fangdd $78 Million – IPO 


    • Applied Therapeutics $40 Million IPO 


    • NextCure – $86 Million IPO 


    • Neuronetics – $108 Million IPO 


    • Gamida Cell – $50 Million IPO 


    • AGNC Closes $507.2 Million Mortgage REIT Equity Offering 


    • Underwriters: $1 billion Mobileye IPO 


    • Semiconductor Developer Aquantia Closes $71 Million IPO 


    • Zealand Pharma – $89 Million IPO 


    • UroGen – $66.9 Million IPO 


    • Selecta Biosciences – $74 Million IPO 


    • Translate Bio – $122 Million IPO 


    • Inotek Pharmaceuticals – $50 Million Follow-On 


    • Syndax – $58 Million IPO 


    • Arbor Realty Trust Closes $77.9 Million Mortgage REIT Equity Offering 


    • Underwriters: $58 million Syndax IPO